By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Portola Pharmaceuticals, Inc. 

270 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-246-7000 Fax: 650-246-7376


SEARCH JOBS

Portola Pharmaceuticals, Inc. was founded in 2003 and is headquartered in South San Francisco, CA. We completed an initial public offering in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 80 employees. At Portola, our goal is to build an enduring biopharmaceutical company with compounds from our own research efforts that advance the care of patients in the areas of thrombosis (blood clots), other hematologic (blood) disorders and inflammation. Our development-stage portfolio includes three 100 percent-owned clinical-stage assets; betrixaban and andexanet alfa (PRT4445), which address significant unmet medical needs in the areas of thrombosis; and PRT2070, an orally available kinase inhibitor with unique pharmacologic properties that targets hematologic cancers.


Key Statistics


Email: info@portola.com
Ownership: Private

Web Site: Portola
Employees:
Symbol: 
 




Segment
Start Up





Company News
Portola Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not 6/25/2015 6:38:01 AM
Wonder Drug Meets All Endpoints for Portola, Bristol-Myers Squibb (BMY) and Pfizer (PFE) 6/22/2015 7:20:36 AM
Portola Pharmaceuticals, Inc. Appoints Industry Leader Tao Fu As Executive Vice President, Chief Commercial And Business Officer 6/15/2015 9:08:57 AM
Portola Pharmaceuticals, Inc. Announces Upcoming Data Presentations On Andexanet Alfa At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress 6/10/2015 8:15:34 AM
Portola Pharmaceuticals, Inc. To Present At Goldman, Sachs & Co. 36th Annual Global Healthcare Conference 6/3/2015 12:41:03 PM
ASCO15: Portola Pharmaceuticals, Inc. Presents Updated Data From Ongoing Phase I/IIa Study Of Dual Kinase Inhibitor Cerdulatinib 5/29/2015 8:42:46 AM
Portola Pharmaceuticals, Inc. Announces Upcoming Data Presentation On Dual Kinase Inhibitor Cerdulatinib At ASCO Annual Meeting 5/18/2015 10:10:56 AM
Portola Pharmaceuticals, Inc. Reports First Quarter 2015 Financial Results And Provides Corporate Update 5/7/2015 8:05:29 AM
Portola Pharmaceuticals, Inc. To Present At Bank of America (BAC) 2015 Health Care Conference 5/5/2015 10:47:08 AM
Portola Pharmaceuticals, Inc. Announces Collaboration With Ora, Inc. For Syk-Selective Inhibitor (PRT2761) In Ophthalmic Diseases 5/5/2015 8:10:25 AM
12345678910...
//-->